Fundraising FoxBiotech Startups
11,136 companies tagged Biotech, with their investors and founders.
Shuttle Pharmaceuticals operates Molecule.ai, an AI-driven software platform for molecular discovery and early-stage drug development. The platform helps researchers explore chemical space and evaluate molecular candidates to support decision-making in the earliest stages of drug development.
0 investors
0 investors
Westlake Village dermatology company developing late-stage topical and photoparticle skin treatments; assets sold to Sebacia in 2020.
0 investors
0 investors
0 investors
SignPath Pharma develops small-molecule therapeutics to prevent cardiotoxicity caused by cancer treatments and other primary therapies. The company focuses on cardio-oncology, designing molecules to protect cardiac function in patients undergoing cancer therapy.
0 investors
0 investors
0 investors
Silo Pharma is a developmental-stage biopharmaceutical company (Nasdaq: SILO) developing novel formulations of traditional and psychedelic therapeutics for underserved conditions such as stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. Its pipeline includes programs for PTSD, fibromyalgia, Alzheimer's, and multiple sclerosis, pursued via the FDA 505(b)(2) pathway in collaboration with academic research partners.
0 investors
Silver Creek develops growth factor-based therapeutics to promote cell survival and growth in response to injury. The company focuses on rescuing damaged cells through targeted biologic interventions.
0 investors
Simplicia builds Atlas, an AI system that scores cross-cultural medical evidence — including traditional pharmacopoeia, ethnobotanical science, and modern pharmacology — with citation-bound provenance and routes findings toward development paths such as NCE, 505(b)(2), or clinically-formulated dietary supplements. It serves drug developers and institutions working on natural-product discovery.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
Sinopia Bio is a biotechnology company developing a therapeutic pipeline focused on Parkinson's disease. It operates a drug discovery platform aimed at changing the trajectory of the disease.
0 investors
SiO2 Materials Science develops precision molded polymer containers with thin glass-like barrier coatings for pharmaceutical and biopharmaceutical applications. Its product line includes syringes, vials, and blood tubes designed for uses such as high-viscosity and high-pH formulations and cold storage.
0 investors
0 investors
0 investors
Sirnaomics is an RNA therapeutics company developing RNA interference (RNAi) drugs using its proprietary PNP (Peptide Nanoparticle) delivery platform for extra-hepatic delivery and its GalAHead technology for controlling therapeutic duration. Its pipeline spans oncology, regenerative and aesthetic medicine, and cardiovascular and metabolic diseases.
0 investors
0 investors
Sisu Pharma develops therapeutics targeting Heat Shock Factor 1 (HSF1), using its HI-LiTe platform to create selective HSF1 degraders for oncology and HSF1 activators for neurodegenerative diseases. Its compounds are aimed at therapy-resistant cancers and other difficult-to-treat diseases.
0 investors